Screener
TG Therapeutics TGTX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Other selling, general and administrative | 62,325 | 43,541 | 135,467 | 82,232 |
| Total selling, general and administrative | 82,130 | 55,585 | 170,347 | 105,916 |
| Total costs and expenses | 218,661 | 106,305 | 388,784 | 218,539 |
| Operating income | 21,674 | 34,843 | 56,469 | 43,465 |
| Other expense (income): | ||||
| Interest expense | 16,572 | 6,716 | 24,238 | 13,473 |
| Loss on extinguishment of debt | — | — | 9,153 | — |
| Other income | (5,132) | (2,793) | (7,519) | (6,396) |
Document
FAQ
- What is TG Therapeutics's operating income?
- TG Therapeutics (TGTX) reported operating income of $21.67M in Q2 2026.
- How has TG Therapeutics's operating income changed year-over-year?
- TG Therapeutics's operating income decreased by 37.8% year-over-year, from $34.84M to $21.67M.
- What is the long-term trend for TG Therapeutics's operating income?
- Over 3 years (2021 to 2025), TG Therapeutics's operating income has grown at a -29.0% compound annual growth rate (CAGR), from -$344.77M to $123.32M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about TG Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude